Subcutaneous adipose tissue is a positive predictor for bone mineral density in prepubertal children with Prader-Willi syndrome independent of lean mass
- PMID: 35286052
- DOI: 10.1515/jpem-2021-0749
Subcutaneous adipose tissue is a positive predictor for bone mineral density in prepubertal children with Prader-Willi syndrome independent of lean mass
Abstract
Objectives: Emerging evidence suggests a fat depot-specific relationship with bone mineral density (BMD) in children, particularly in those who are overweight/obese. However, this has not yet been investigated in detail in children with Prader-Willi syndrome (PWS), a genetic syndrome characterized by a decreased lean mass (LM) and increased fat mass (FM). The objective of this study is to investigate the relationships of LM and FM, particularly fat distribution, with bone mineral parameters.
Methods: This is a retrospective and cross-sectional study. Forty-seven prepubertal Japanese children with PWS (22 males, mean age: 6.86 years) were included. No subjects had type 2 diabetes mellitus or osteoporotic medications. LM, FM, and BMD and bone mineral content in the total body less head and the lumbar spine were measured using dual-energy x-ray absorptiometry, in addition to subcutaneous/visceral adipose tissue (SAT/VAT), and the ratio of VAT to SAT (V/S) by computed tomography at the umbilical level. Bone mineral apparent density was calculated to correct for bone size.
Results: LM positively correlated with bone mineral parameters after controlling for age, sex, growth hormone (GH) treatment, and FM. Although FM did not correlate with bone mineral parameters, compartment-specific analysis revealed that SAT positively and V/S negatively correlated with bone mineral parameters after controlling for age, sex, GH treatment and LM.
Conclusions: A compartment-specific effect of FM on bone mineral parameters was noted such that SAT was a positive predictor for BMD independent of LM in prepubertal children with PWS.
Keywords: Prader–Willi syndrome; adiposity; bone mineral density; children; fat distribution.
© 2022 Walter de Gruyter GmbH, Berlin/Boston.
Similar articles
-
Relative Contributions of Lean and Fat Mass to Bone Mineral Density: Insight From Prader-Willi Syndrome.Front Endocrinol (Lausanne). 2018 Aug 22;9:480. doi: 10.3389/fendo.2018.00480. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 30186239 Free PMC article.
-
Visceral adipose tissue increases shortly after the cessation of GH therapy in adults with Prader-Willi syndrome.Endocr J. 2018 Nov 29;65(11):1127-1137. doi: 10.1507/endocrj.EJ18-0107. Epub 2018 Sep 4. Endocr J. 2018. PMID: 30185718
-
Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial.J Clin Endocrinol Metab. 2009 Oct;94(10):3763-71. doi: 10.1210/jc.2009-0270. Epub 2009 Jul 21. J Clin Endocrinol Metab. 2009. PMID: 19622627 Clinical Trial.
-
Visceral adiposity and inflammatory bowel disease.Int J Colorectal Dis. 2021 Nov;36(11):2305-2319. doi: 10.1007/s00384-021-03968-w. Epub 2021 Jun 9. Int J Colorectal Dis. 2021. PMID: 34104989 Review.
-
The use of growth hormone therapy in adults with Prader-Willi syndrome: A systematic review.Clin Endocrinol (Oxf). 2021 Apr;94(4):645-655. doi: 10.1111/cen.14372. Epub 2020 Dec 9. Clin Endocrinol (Oxf). 2021. PMID: 33296095
Cited by
-
High levels of LIGHT/TNFSF14 in patients with Prader-Willi syndrome.J Endocrinol Invest. 2023 Sep;46(9):1901-1909. doi: 10.1007/s40618-023-02050-2. Epub 2023 Mar 14. J Endocrinol Invest. 2023. PMID: 36917420 Free PMC article.
References
-
- Cassidy, SB, Schwartz, S, Miller, JL, Driscoll, DJ. Prader–Willi syndrome. Genet Med 2012;14:10–26, https://doi.org/10.1038/gim.0b013e31822bead0.
-
- Irizarry, KA, Miller, M, Freemark, M, Haqq, AM. Prader Willi syndrome: genetics, metabolomics, hormonal function, and new approaches to therapy. Adv Pediatr 2016;63:47–77, https://doi.org/10.1016/j.yapd.2016.04.005.
-
- Passone, CGB, Franco, RR, Ito, SS, Trindade, E, Polak, M, Damiani, D, et al.. Growth hormone treatment in Prader–Willi syndrome patients: systematic review and meta-analysis. BMJ Paediatr Open 2020;4: e000630, https://doi.org/10.1136/bmjpo-2019-000630.
-
- Deal, CL, Tony, M, Hoybye, C, Allen, DB, Tauber, M, Christiansen, JS. Growth hormone research society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader–Willi syndrome. J Clin Endocrinol Metab 2013;98:E1072–87, https://doi.org/10.1210/jc.2012-3888.
-
- Vestergaard, P, Kristensen, K, Bruun, JM, Ostergaard, JR, Heickendorff, L, Mosekilde, L, et al.. Reduced bone mineral density and increased bone turnover in Prader-Willi syndrome compared with controls matched for sex and body mass index--a cross-sectional study. J Pediatr 2004;144:614–9, https://doi.org/10.1016/j.jpeds.2004.01.056.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials